Aiming to become the global leader in chip-scale photonic solutions by deploying Optical Interposer technology to enable the seamless integration of electronics and photonics for a broad range of vertical market applications

Free
Message: POET like a fase 3 biopharma waiting for results.

The good thing about POET verus Biopharm is that it is not a yes/no with the FDA. POET has been substantially derisked in the past 2 years and the main risks are being well managed based on what we have heard and seen combined with 3rd party verification and by very knowledgeable new executives.

There is still timing, execution and cost risks.

Share
New Message
Please login to post a reply